Estrella Immunopharma activates second clinical site for Phase I/II STARLIGHT-1 NHL trial

Estrella Immunopharma, Inc.

Baylor Research Institute in Dallas, TX now open for patient enrollment in STARLIGHT-1 trial.
Trial evaluates EB103, a CD19-Redirected ARTEMIS T-cell therapy for relapsed/refractory B-cell NHL.
Open-label, dose escalation/expansion Phase I/II study to determine Recommended Phase II Dose in adults ≥18.
CEO Cheng Liu states partnership will accelerate development and increase patient access to EB103.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.